Molecular epidemiology of HIV infection in portuguese migrant population by Pingarilho, M et al.
MOLECULAR EPIDEMIOLOGY AND HIV-1	DRUG RESISTANCE IN
INFECTED AFRICANMIGRANTS FOLLOWED-UP IN PORTUGAL
Ana	Abecasis
on behalf of the Portuguese	HIV-1	Drug Resistance Study Group
ana.abecasis@ihmt.unl.pt
• In	2015,	 37%	of	new	HIV	
diagnosis	 in	the	EU	were	
among	 migrants.
European	Centre	for	Disease	Prevention	and	Control	(ECDC),	WHO	Regional	Office	for	Europe:	HIV/AIDS	surveillance	in	Europe	2015.
HIV	INFECTION IN MIGRANTS IN EUROPE
Higher proportions of people from Sub-Saharan Africa and South and South-
East Asia (both 56%) had CD4 counts of below 350 cells per mm3 at
diagnosis than non-migrants (47%) and other migrant groups (Figure 1.8).
HIV	INFECTION IN MIGRANTS IN EUROPE
• Some studies indicate that many of the migrants, even those originating
from regions of high HIV prevalence, acquire HIV after arriving in the
EU.
• This indicates that prevention strategies need to be developed
specifically for this vulnerable population.
HIV	INFECTION IN MIGRANTS IN EUROPE
Geographic origin of HIV-1	cases	diagnosed in	Portugal	per	year
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In	Portugal,	in	2015,	24.8%	of	the	new	HIV	cases	were	diagnosed	among	migrants,	18.6%	of	which	
in	migrants	from	Sub-Saharan	Africa.	
HIV	INFECTION IN MIGRANTS IN PORTUGAL
- To analyze the molecular epidemiology of HIV-1 infection in migrants originating from
Portuguese speaking African countries, followed up in Portugal.
- To analyze the prevalence and characteristics of Transmitted Drug Resistance (TDR) in
migrants originating from Portuguese speaking African countries.
- To analyze the prevalence and characteristics of Acquired Drug Resistance (ADR) in migrants
originating from Portuguese speaking African countries.
OBJECTIVES
- Observational retrospective study with convenience sampling.
- Patients selected from the Portuguese HIV Drug Resistance, which includes clinical,
demographic and genomic (Sanger sequencing for drug resistance testing) information from
patients followed up in several portuguese hospitals, ranging from North to South of the
country.
- Patients included originated from Portuguese speaking African countries: Angola,
Mozambique, Guinea-Bissau and Cape Verde.
- Data was collected between July 2001 and December 2014.
- 855 patients were included:
- 537 (63%) before starting antiretroviral (ARV) treatment;
- 303 (35%) after starting ARV treatment.
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DISTRIBUTIONOF HIV-1	SUBTYPES IN MIGRANTS
Most prevalent subtypes:
• CRF02_AG	(26.4%)	
• Unique Recombinant Forms (20.2%)
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MOLECULAREPIDEMIOLOGYOF HIV-1	INFECTION INAFRICANMIGRANTS
FOLLOWEDUP INPORTUGAL:	CONCLUSIONS
- There	 is	a	gradual	increase	 of	CRF02_AG	in	migrants	followed	up	in	Portugal
- The	prevalence	 of	HIV-1	subtypes	 in	migrants	 largely	varies	and	is	consistent	with	the	
subtype	distribution	 at	the	patients’	 country	of	origin.
- This	compartmentalization	 of	HIV-1	subtypes	 according	to	the	country	of	origin	may	
indicate:
We’re trying to	
answer these
questions through
two other projects:
BEST-HOPE	and
MIGRANT-HIV.
- The	migrants	are	infected	predominantly	 in	
Portugal,	but	inside	 communities	 of	migrants	
from	the	same	country	and/or;
- The	migrants	are	infected	 in	their	country	of	
origin	and	arrive	to	Portugal	already	infected	
with	HIV-1
HIV-1	DRUG RESISTANCE IN AFRICANMIGRANTS
FOLLOWEDUP IN PORTUGAL
ADR in	treated	patients:
63.4%	 (192/303)[95%	 CI,	57.8-68.6]
• Single class ADR
18.2% (55)[95% CI, 4.1-8.1]
• Double class ADR
39.6% (120)[95% CI, 34.3-45.4]
• Triple class ADR
5.6% (17)[95% CI, 1.0-3.3]
TDR in	DN	patients:
7.8% (42/537)[95%	 CI,	5.8-10.4]	
• Single	class	TDR
5.8%	 (31)	[95%	CI,	4.1-8.1]
• Double	class	TDR
1.9%	 (10)	[95%	CI,	1.0-3.4]
• Triple	class	TDR
n=1
TDR Angola	%	(n)
Cape	Verde	
%	(n)
Guinea-Bissau
%	(n)
Mozambique
%	(n)
Overall
%	(n)
TDR	any class 6.3	(10) 6.8	(10) 10.6 (18) 6.6	(4) 7.8	(42)
NRTIs TDR 3.1	(5) 3.4	(5) 5.9	(10) 3.3	(2) 4.1	(22)
NNRTIs TDR 6.3	(10) 3.4	(5) 5.3	(9) 6.6	(4) 5.2	(28)
PIs TDR 0.0 1.4 (2) 1.2	(2) 0.0 0.7	(4)*
HIV-1	TDR	IN AFRICANMIGRANTS FOLLOWEDUP IN PORTUGAL
*	Indicates	 value	significantly	 different	 from	 the	corresponding	 value	 calculated	 in	the	HIV-1	 portuguese population.	
HIV-1	ADR	IN AFRICANMIGRANTS FOLLOWEDUP IN PORTUGAL
ADR Angola%	(n)
Cape	Verde
%	(n)
Guinea-Bissau
%	(n)
Mozambique
%	(n)
Overall
%	(n)
ADR	any class 68.5	(74) 71.7	(71) 45.9	(34) 59.1	(13) 63.4	(192)*
NRTIs ADR 59.3	(64) 56.6	(56) 39.2	(29) 45.5	(10) 52.5	(159)*
NNRTIs ADR 47.2	(51) 56.6	(56)* 31.1	(23) 36.4	(8) 45.5	(138)
PIs ADR 16.7	(18) 16.2	(16) 14.9	(11) 18.2	(4) 16.2	(49)*
*	Indicates	 value	significantly	 different	 from	 the	corresponding	 value	 calculated	 in	the	HIV-1	 portuguese population.	
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HIV-1	DRUG RESISTANCE IN AFRICANMIGRANTS
FOLLOWEDUP IN PORTUGAL:	CONCLUSIONS
7.8% TDR in migrants
ü Not significantly different from the portuguese HIV-1 population of the Drug Resistance
database, except for PIs where rates of TDR were significantly lower in migrants
ü Increasing rates of TDR to NRTIs in the last years.
ü Other studies:
ü 8.4% TDR in a similar study with African immigrants in Spain (1996-2010) and 13%
between 2007-2010
ü In an ongoing prospective study (BESTHOPE), we found 9.3% TDR in the population
of migrants (n=54) included (2015-2017)
63.4% ADR in migrants
ü Significantly lower than the rates of ADR for the portuguese HIV-1 population of the
Drug Resistance database, except for NNRTIs however
ü Increasing rates of ADR to all classes since 2011
ü Migrants from Guinea-Bissau presented the lower rates of ADR 45.9% (despite higher
rates of TDR – 10.6%)
ü Migrants from Cape Verde presented the higher rates of ADR (71.7%), with
significantly higher rates of NNRTIs ADR than portuguese patients.
HIV-1	DRUG RESISTANCE IN AFRICANMIGRANTS
FOLLOWEDUP IN PORTUGAL:	CONCLUSIONS
• Prospectives studies ongoing: Best-Hope e Migrant-HIV (newly diagnosed
patients)
• To compare the results of migrants with the population of patients
originated and living in each one of these 4 countries: Angola, Mozambique,
Guinea-Bissau and Cape Verde
• To use transmission chain reconstruction to further analyse these results.
PERSPECTIVES
BEST	HOPE	ANDMIGRANT	HIV
• Objectives:
• To analyse and characterize TDR in newly diagnosed patients in Portugal;
• To determine clinical and socio-behavioral risk factors for acquiring HIV infection,
whether or not associated with TDR;
• To analyse risk factors for transmission of HIV, with or without TDR, in specific
vulnerable populations (MSMs and migrants) – through socio-behavioral
questionnaires, specifically designed for each population, combined with
phylogenetic reconstruction of transmission chains and drug resistance data;
- “Genomics, socio-behavioral and clinical data to
prevent HIV transmission in migrants: an innovative
approach” (FCT PTDC/DTP-EPI/7066/2014)
- GHTM-UID/Multi/04413/2013
- HIV-ERA BEST HOPE (HIVERA/0001/2011)
- L’Oréal Portugal Medals of Honor for Women in
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